Emman Shubbar

Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors
Viktor Sandblom, Johan Spetz, Emman Shubbar, Mikael Montelius, Ingun Ståhl et al.
PLoS ONE, Journal article 2020
Journal article

Cluster-based evaluation of T2* for early and longitudinal tumor radiotherapy response assessment in a small-intestine neuroendocrine tumor model
Mikael Montelius, Lukas Lundholm, Oscar Jalnefjord, Emman Shubbar, John Swanpalmer et al.
Magnetic Resonance Materials in Physics, Biology and Medicine, Conference paper 2019
Conference paper

Early assessment of external beam radiotherapy response in an animal model of small-intestine neuroendocrine tumour (GOT1) using VERDICT modelling of diffusion MR data
Lukas Lundholm, Mikael Montelius, Oscar Jalnefjord, Emman Shubbar, John Swanpalmer et al.
Magnetic Resonance Materials in Physics, Biology and Medicine, Conference paper 2019
Conference paper

Extended survival with fractionated 177Lu-octreotate treatment for neuroendocrine tumor GOT1-bearing female BALB/c nude mice
Mikael Elvborn, Emman Shubbar, Eva Forssell-Aronsson
5th Swedish Cancer Research Meeting, Umeå, 2019, 3-4 October, Conference contribution 2019
Conference contribution

Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer.
Viktor Sandblom, Johan Spetz, Emman Shubbar, Mikael Montelius, Ingun Ståhl et al.
PloS One, Journal article 2019
Journal article

Tyrosine kinase inhibitors can potentially increase the effect from radiation therapy on medullary thyroid cancer
Viktor Sandblom, Johan Spetz, Emman Shubbar, Mikael Montelius, Ingun Ståhl et al.
Gothenburg Cancer Meeting. 6-7th May 2019, Poster 2019
Poster

Transcriptional effects of Lu-177-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice
Johan Spetz, Britta Langen, Nils Rudqvist, Toshima Z Parris, Emman Shubbar et al.
Ejnmmi Research, Journal article 2019
Journal article

177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
Tobias Hofving, Viktor Sandblom, Yvonne Arvidsson, Emman Shubbar, Gülay Altiparmak et al.
Endocrine-Related Cancer, Journal article 2019
Journal article

Tyrosinkinashämmare kan öka effekten från strålbehandling av medullär tyreoideacancer
Viktor Sandblom, Johan Spetz, Emman Shubbar, Mikael Montelius, Ingun Ståhl et al.
Nationellt möte om sjukhusfysik, Poster 2019
Poster

rA1M, a kidney protector during PRRT?
Charlotte Andersson, Emman Shubbar, Bo Åkerström, Magnus Gram, Eva Forssell-Aronsson
European Radiation Protection Week, Stockholm, Sweden, 2019, 14-18 October, Conference contribution 2019
Conference contribution

The protective antioxidant rA1M allows full antitumor effects of 177Luoctreotate treatment in PDX neuroendocrine tumor models
Charlotte Andersson, Emman Shubbar, Emil Schüler, Bo Åkerström, Magnus Gram et al.
Gothenburg Cancer meeting, Gothenburg, Sweden, 2019, May 6-7, Conference contribution 2019
Conference contribution

Recombinant alpha(1)-Microglobulin Is a Potential Kidney Protector in Lu-177-Octreotate Treatment of Neuroendocrine Tumors
Charlotte Andersson, Emman Shubbar, E. Schuler, B. Akerstrom, M. Gram et al.
Journal of Nuclear Medicine, Journal article 2019
Journal article

The effect of timing and sequence of gemcitabine administration and ionizing radiation for more efficient treatment of medullary thyroid carcinoma
Emman Shubbar, Viktor Sandblom, John Swanpalmer, Eva Forssell-Aronsson
Gothenburg Cancer Meeting, Poster 2019
Poster

Vandetanib may act as radiosensitiser for 177Lu-octreotate treatment of medullary thyroid cancer
Viktor Sandblom, Johan Spetz, Emman Shubbar, Ingun Ståhl, John Swanpalmer et al.
2nd European Congress of Medical Physics. Physica Medica Vol. 52, Suppl. 1, pp. 62-63, Conference paper 2018
Conference paper

The effect of timing and sequence of gemcitabine administration and radiation for the treatment of medullary thyroid carcinoma.
Emman Shubbar, Viktor Sandblom, John Swanpalmer, Eva Forssell-Aronsson
European Journal of Nuclear Medicine and Molecular Imaging, Conference contribution 2018
Conference contribution

Better therapeutic results after fractionated administration of Lu-177-octreotate in mice bearing human neuroblastoma
Arman Romiani, Johan Spetz, Emman Shubbar, Ruth H. Palmer, Bengt Hallberg et al.
The European Association of Nuclear Medicine (EANM) , Poster 2018
Poster

Adenine-Induced Chronic Renal Failure in Rats: A Model of Chronic Renocardiac Syndrome with Left Ventricular Diastolic Dysfunction but Preserved Ejection Fraction
Pavlos Kashioulis, Jaana Lundgren, Emman Shubbar, Lisa Nguy, Aso Saeed et al.
Kidney & Blood Pressure Research, Journal article 2018
Journal article

Co-administration of rA1M during 177Lu-octreotate treatment does not interfere with the therapeutic effect
Charlotte Andersson, Emman Shubbar, Bo Åkerström, Magnus Gram, Eva Forssell-Aronsson
The North American Neuroendocrine Tumor Society, Seattle, 2018, Oktober 4-6, Conference contribution 2018
Conference contribution

Potential protection of renal function in 177Lu-octreotate treatment using alpha-1-microglobulin
Charlotte Andersson, Emman Shubbar, Bo Åkerström, Magnus Gram, Eva Forssell-Aronsson
The European Association of Nuclear Medicine , Düsseldorf, 2018, Oktober 13-17, Conference contribution 2018
Conference contribution

Kidney protection during treatment with 177Lu-octreotate using recombinant alpha-1-microglobulin
Charlotte Andersson, Emman Shubbar, Bo Åkerström, Magnus Gram, Eva Forssell-Aronsson
The Swedish Radiation Research Association for young Scientists Workshop , Uppsala, 2018, Augusti 29-31, Conference contribution 2018
Conference contribution